Head & Neck Cancer Drugs Market
                     Head & Neck Canc
er Drugs Market
The Global head & neck cancer drugs market was valued at US$ 1.16 Billion in 
2020 and is expected to reach US$ 2.98 Billion by 2030, growing at a CAGR of 
9.6% from 2021 – 2030.
[email protected]
Copyright © 2021 Accurize Market Research
Report Description
Head & neck cancer is a term used to define different malignant 
tumors that develop from tissues in the oral cavity, throat, nose, 
sinuses, salivary glands, and skin of the face. Most of the head & 
neck cancers are squamous cell carcinomas. If cancer is found 
only in the squamous layer of cells, it is called carcinoma in situ. 
If cancer has grown beyond this cell layer and moved into the 
deeper tissue, then it is called invasive squamous cell carcinoma. 
Symptoms of head & neck cancer include sore throat, unusual 
bleeding, numbness, swelling, facial pain, and visible lumps. In 
rare cases, the patient has trouble breathing as well. The core 
reason for head & neck cancer is excessive consumption of alcohol 
and tobacco, increasing cases linked to human papillomavirus, 
prolonged sun exposure, poor dental and oral hygiene, poor 
nutrition, and inappropriate occupational & environmental 
inhalants. Prevention measures include avoiding alcohol, smoking, 
using sunscreen reducing risks of HPV infection, and maintaining 
dentures. Drugs such as Pembrolizumab (Keytruda) by Merck & 
Company and Nivolumab (Opdivo), developed by Bristol-Myers 
Squib are further augmenting the market growth vigorously.
[email protected]
Copyright © 2021 Accurize Market Research
Market Dynamics
High prevalence of head & neck cancer globally, technological advancements 
in the diagnosis & screening of cancer, and rise in the demand for combination 
therapy for the treatment are driving the global head & neck cancer drugs 
market. Side effects especially in chemotherapy, the healthy cells of the 
patient are harmed along with the malignant cells, and these factors are highly 
restricting the market growth. However, Increased R&D activities in the 
therapeutic sector coupled with novel pipeline drugs such as Atezolizumab, 
Ipilimumab, Avelumab, Erlotinib, Durvalumab, Afatinib, Bevacizumab, and 
others. The consumption of alcohol & tobacco in an excessive manner is 
further leading to increased cases of head & neck cancer hence pouring the 
growth of the global head & neck cancer drugs market growth.
[email protected]
Copyright © 2021 Accurize Market Research
Market Segmentation
The global head & neck cancer drugs market is fragmented into Drug class, Sales Channel, and 
Region. By Drug class, the global market is bifurcated into Chemotherapy, Immunotherapy, and 
Targeted therapy. Chemotherapy segmented dominated the global market among the Drug Class 
segment owing to its high usage during radiation therapies. bleomycin, cetuximab, docetaxel, 
paclitaxel, capecitabine, hydroxyurea, methotrexate, docetaxel, 5-fluorouracil, and methotrexate are 
the most effective available drugs among others. Based on Sales channel, the global market is 
classified into Hospital Pharmacies, Drug stores & Retail pharmacies, and Online stores. Drug stores & 
retail pharmacies are dominating the global market owing to their high presence in the market. The 
online stores segment is expected to foresee high growth during the forecast period.
Geography Analysis
– Based on Region, the global head & neck cancer drugs market is segmented into North 
America, Europe, Asia-Pacific, and Rest of the World. North America is further classified into 
the U.S., Canada, and Mexico. Europe is further segmented into Germany, the U.K., France, 
Italy, Spain, Russia, and the rest of Europe. Asia-Pacific is segmented into China, Japan, 
India, Australia, South Korea, and the rest of APAC. The RoW includes South & Central 
America, the Middle East, and Africa. Currently, APAC is dominating the global market 
among all the geographies owing to the key market players, high prevalence of head & neck 
cancer, and high consumption of tobacco & alcohol in the region.
– Prominent players of the global head & neck cancer drugs market are Bristol-Myers Squibb 
Company, AstraZeneca PLC, Eli Lilly and Company (ARMO Biosciences), F. Hoffmann-La 
Roche Ltd. (Genentech, Inc.), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), 
AstraZeneca PLC, Immutep Limited, Novartis AG, Merck KGaA (EMD Serono, Inc.), Pfizer 
Inc., and Merck & Co., Inc., among others.
[email protected]
Copyright © 2021 Accurize Market Research
CAGR 9.6 (2021 – 2030)
[email protected]
Copyright © 2021 Accurize Market Research
Market Segmentation and Scope of 
the Global Antifungal Drug Market
By Drug class
• Chemotherapy
• Immunotherapy
• Targeted therapy
By Sales Channel
• Hospital Pharmacies
• Drug stores & Retail pharmacies
• Online stores
[email protected]
Copyright © 2021 Accurize Market Research
Report Features
[email protected]
Copyright © 2021 Accurize Market Research
Prominent Players
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Eli Lilly and Company (ARMO Biosciences)
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
• Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
• AstraZeneca PLC
• Immutep Limited
• Novartis AG
• Merck KGaA (EMD Serono, Inc.)
• Pfizer Inc.
• Merck & Co., Inc.
• Others
[email protected]
Copyright © 2021 Accurize Market Research
Contact Us
Accurize Market Research Pvt. Ltd
PATNA OFFICE: K-129, PC COLONY, 
HANUMAN NAGAR, 
KANKARBAGH, PATNA, PIN-800020
Email: [email protected]
CONTACT NO:+1-339-368-6383
[email protected]
Copyright © 2021 Accurize Market Research